In LPS-stimulated human THP-1 cells, BIRB-796 inhibited TNFα release with a reported IC50 of 18 ± 3 nM. The paper does not define the ± statistic for this endpoint. [1]
Allosteric binding conformation
Biochemical assay · Human p38 MAP kinase–BIRB796 co-crystal [1]
The BIRB796 complex adopts the DFG-out conformation and contacts an allosteric pocket as well as the ATP-site region.
Literature-Reported Treatment Conditions
- Method
- Co-crystal structure determination; comparison with compound 1 and earlier ATP-site structures.
- Reported limits
- Compound purity and salt specification were not provided in the read main text.
Methods and source locations
Compound reported in the paper: Doramapimod (BIRB-796); Compound label in the paper: BIRB 796
Evidence concerns the reported research material; no Adooq lot equivalence or salt conversion is established.
p.269, Figure 3c and BIRB 796 structural section; p.271, Table 1 and crystallographic Methods
BIRB796 co-crystal diffraction resolution: X-ray crystallography — p.269 structural Results; p.271 Table 1
Slow binding to p38 MAP kinase
Biochemical assay · Purified human p38 MAP kinase [1]
BIRB796 showed slow association and dissociation in fluorescence competition experiments.
Literature-Reported Treatment Conditions
- Treatment concentration
- Figure 4c: 174 nM kinase and 290 nM BIRB796.
- Exposure duration
- BIRB796 half-reaction preincubation: 60 min; fluoroprobe half-reaction: 3 min.
- Method
- Exchange curves fitted to simple competitive binding.
- Reported limits
- Figure 1 does not define the ± statistic or replicate count; no uncertainty type is assigned.
Methods and source locations
Compound reported in the paper: Doramapimod (BIRB-796); Compound label in the paper: BIRB 796
Evidence concerns the reported research material; no Adooq lot equivalence or salt conversion is established.
p.268 Figure 1; p.270 Figure 4c and kinetic Results; p.271 Binding studies
Binding affinity calculated as koff/kon at 23 °C: Competitive fluorescence binding using SK&F 86002 — p.268 Figure 1 and caption
BIRB796 dissociation rate constant: Simultaneous fitting of exchange-curve half-reactions — p.268 Figure 1; p.271 Binding studies
Inhibition of THP-1 TNFα release
Cell-based study · Human THP.1 cells stimulated with LPS [1]
BIRB796 inhibited released TNFα in a cellular ELISA assay.
Literature-Reported Treatment Conditions
- Method
- LPS-stimulated THP.1 assay; released TNFα quantified by commercial ELISA.
- Co-treatment
- LPS stimulation; no second inhibitor combination adopted.
- Reported limits
- Read main text does not specify drug exposure duration, vehicle, tested concentration range, replicate count or meaning of ± for this endpoint.
Methods and source locations
Compound reported in the paper: Doramapimod (BIRB-796); Compound label in the paper: BIRB 796
Evidence concerns the reported research material; no Adooq lot equivalence or salt conversion is established.
p.268 Figure 1; p.271 cellular Methods
Inhibition of LPS-induced TNFα release: TNFα ELISA, with compound-present and compound-absent conditions — p.268 Figure 1; p.271 cellular Methods